US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001
US FDA grants fast track designation to Rznomics’ gene therapy-based cancer drug candidate, RZ-001: Seongnam, South Korea Wednesday, February 19, 2025, 16:00 Hrs [IST] Rznomics, ...
The US FDA has granted fast track designation to Rznomics' RZ-001 for the treatment of hepatocellular carcinoma (HCC).
Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Hepatocellular Carcinoma (HCC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results